nach oben

Erschienen in:

01.11.2015 | original article

Impaired coronary blood flow may be related to elevated homocysteine levels in patients with metabolic syndrome

verfasst von: Yusuf I. Alihanoglu, MD, Bekir S. Yildiz, MD, Emin E. Özcan, MD, Dogu I. Kilic, MD, Deniz S. Kuru, MD, Ozgur Taskoylu, MD, Halil Tanriverdi, MD, Havane A. Kaftan, MD, Harun Evrengul, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2015

Einloggen, um Zugang zu erhalten

Summary

Background

Metabolic syndrome (MS) refers to a group of cardiovascular risk factors associated with endothelial dysfunction and impaired coronary blood flow (CBF). Homocysteine (Hcy) is another risk factor for the development of insulin resistance and endothelial dysfunction. However, the relationship between Hcy levels and CBF in patients with MS has not been investigated specifically. In the present study, we aimed to evaluate the relationship between Hcy levels and CBF in MS patients with normal coronary arteries.

Methods

The study population included 36 patients with MS (20 males, 16 females; mean age = 55 ± 9 years) and 36 control subjects (20 males, 16 females; mean age = 51 ± 7 years). All subjects had angiographically proven normal coronary arteries. Plasma Hcy concentrations were evaluated after a fast of 12 h or longer. The CBF rates of all subjects were documented by the thrombolysis in myocardial infarction (TIMI) frame count method.

Results

The TIMI frame counts for each major epicardial coronary artery and mean TIMI frame count were found to be significantly higher in the MS group compared with the control group (left anterior descending coronary artery (LAD): 53 ± 26 vs. 39 ± 17; p = 0.01, left circumflex artery (LCx): 32 ± 12 vs. 26 ± 11; p = 0.01, right coronary artery (RCA): 33 ± 14 vs. 26 ± 12; p = 0.02, mean TIMI frame count: 39 ± 16 vs. 20 ± 12; p = 0.01). Plasma Hcy levels in patients with MS were significantly higher compared with controls (MS group = 11.6 ± 4 and control group = 9.6 ± 2.6; p = 0.01). Additionally, plasma Hcy levels were positively correlated with each calculated TIMI frame count value in the MS group (LAD, r: 0.28 and p = 0.006; LCx, r: 0.25 and p = 0.022; RCA, r: 0.26 and p = 0.042; mean TIMI frame count, r: 0.28 and p = 0.004).

Conclusion

Plasma Hcy levels and TIMI frame counts were significantly higher in patients with MS. Impaired CBF in MS may be related to elevated levels of Hcy, even if Hcy levels are normal.

Vorheriger Artikel Assessment of left atrial volume and function in patients with psoriasis by using real time three-dimensional echocardiography

Nächster Artikel Evaluation of electrocardiographic parameters in patients with diabetes insipidus

Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutritional examination survey. Circulation. 2004;109:42–6.CrossRefPubMed

Quiñones MJ, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G, De La, Rosa R, Chon Y, Yang H, Nicholas SB, Modilevsky T, Yu K, Van Herle K, Castellani LW, Elashoff R, Hsueh WA. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med. 2004;140:700–8.CrossRefPubMed

Pırat B, Bozbaş H, Şimsek V, Yıldırır A, Sade LE, Gürsoy Y, Altın C, Atar I, Muderrisoglu H. Impaired coronary flow reserve in patients with metabolic syndrome. Atherosclerosis. 2008;201:112–6.CrossRefPubMed

Turhan H, Erbay AR, Yasar AS, Bicer A, Sasmaz H, Yetkin E. Impaired coronary blood flow in patients with metabolic syndrome: documented by Thrombolysis in Myocardial Infarction (TIMI) frame count method. Am Heart J. 2004;148:789–94.CrossRefPubMed

Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.CrossRefPubMed

Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D’Agostino RB Sr, Wilson PW. Framingham offspring study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 2001;24:1403–10.CrossRefPubMed

Virtanen JK, Voutilainen S, Alfthan G, Korhonen MJ, Rissanen TH, Mursu J, Kaplan GA, Salonen JT. Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factors (KIHD) study. J Intl Med. 2005;257:255–62.CrossRef

Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost. 2000;26:227–32.CrossRefPubMed

He L, Zeng H, Li F, Feng J, Liu S, Liu J, Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab. 2010;299:1061–5.CrossRef

10.

Evrengul H, Tanriverdi H, Enli Y, Kuru O, Seleci D, Bastemir M, Kilic A, Kaftan A, Kilic M. Interaction of plasma homocysteine and thyroid hormone concentrations in the pathogenesis of the slow coronary flow phenomenon. Cardiology. 2007;108(3):186–92.CrossRefPubMed

11.

Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M. Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter. 2007;12:298–305.CrossRefPubMed

12.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed

13.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed

14.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–96.CrossRef

15.

Cetin M, Zencir C, Tasolar H, Baysal E, Balli M, Akturk E. The association of serum albumin with coronary slow flow. Wien Klin Wochenschr. 2014;126:468–73.CrossRefPubMed

16.

Epstein SE, Cannon O, Talbot TL. Hemodynamic principles in the control of coronary blood flow. Am J Cardiol. 1985;56:4–10.CrossRef

17.

Fabian E, Kickinger A, Wagner KH, Elmadfa I. Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people. Wien Klin Wochenschr. 2011;123:496–501.CrossRefPubMed

18.

Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–50.CrossRefPubMed

19.

Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3:1646–54.CrossRefPubMed

20.

Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids. 2001;36:13–26.CrossRef

21.

Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL; SMART Study Group. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart. 2007;93:216–20.CrossRefPubMed

22.

Björck J, Hellgren M, Rastam L, Lindblad U. Associations between serum insulin and homocysteine in a Swedish population-a potential link between the metabolic syndrome and hyperhomocysteinemia: the Skaraborg project. Metabolism. 2006;55:1007–13.CrossRefPubMed

23.

Rosolova H, Simon J, Mayer O Jr, Racek J, Dierze T, Jacobsen DW. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res. 2002;51:93–8.PubMed

24.

Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab. 2001;86:719–23.PubMed

25.

Chico A, Pérez A, Córdoba A, Arcelús R, Carreras G, de Leiva A, González-Sastre F, Blanco-Vaca F. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia. 1998;41:684–93.CrossRefPubMed

26.

Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis. 2001;159:497–511.CrossRefPubMed

27.

Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993;57:47–53.CrossRefPubMed

28.

Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J. 2004;3:1–23.CrossRef

29.

Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, Karakaya O. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J. 2005;46:373–82.CrossRefPubMed

30.

Tanriverdi H, Evrengul H, Enli Y, Kuru O, Seleci D, Tanriverdi S, Tuzun N, Kaftan HA, Karabulut N. Effect of homocysteine-induced oxidative stress on endothelial function in coronary slow-flow. Cardiology. 2007;107:313–20.CrossRefPubMed

31.

Arnett EN, Isner JM, Redwood DR, Kent KM, Baker WP, Ackerstein H, Roberts WC, et al. Coronary artery narrowing in coronary heart disease: comparison of cineangiographic and necropsy findings. Ann Intern Med. 1979;91:350–6.CrossRefPubMed

Titel: Impaired coronary blood flow may be related to elevated homocysteine levels in patients with metabolic syndrome
verfasst von: Yusuf I. Alihanoglu, MD
Bekir S. Yildiz, MD
Emin E. Özcan, MD
Dogu I. Kilic, MD
Deniz S. Kuru, MD
Ozgur Taskoylu, MD
Halil Tanriverdi, MD
Havane A. Kaftan, MD
Harun Evrengul, MD
Publikationsdatum: 01.11.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 21-22/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-015-0854-z

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 21-22/2015

Right ventricular and atrial functions in patients with nonischemic dilated cardiomyopathy

Veranstaltungen

Der Pionier der österreichischen Kardiologie Univ.-Prof. Dr. Fritz Kaindl ist am 13. September 2015 im 94. Lebensjahr verstorben

Prognostic significance of transaminases after acute ST-elevation myocardial infarction: insights from a cardiac magnetic resonance study

Rupture of splenic artery aneurysm in primipara five days after cesarean section: case report and review of the literature

A curable cause of hypertension: renal artery pseudoaneurysm